Targeting Liver Tumors: Ascelia CEO Expects 2022 Mangoral Launch
Imaging Agent Mangoral Seen Benefiting From Orphan Drug Status
Executive Summary
The CEO of Ascelia Pharma is confident of a successful pivotal trial for its non-gadolinium imaging agent for the detection of liver tumors that could benefit kidney disease patients.